Publicacións en colaboración con investigadores/as de Erasmus University Medical Center (36)

2024

  1. Mitral Valve Transcatheter Edge-to-Edge Repair: 1-Year Outcomes From the MiCLASP Study

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 7, pp. 890-903

2023

  1. Relationship between stent length and very long-term target lesion failure following percutaneous coronary intervention for ST-elevation myocardial infarction in the drug-eluting stents era: insights from the EXAMINATION-EXTEND study

    American Heart Journal, Vol. 264, pp. 72-82

2022

  1. Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: Final results of the SYNTAX II study

    European Heart Journal, Vol. 43, Núm. 13, pp. 1307-1316

2020

  1. Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: A pooled analysis of individual patient data

    EuroIntervention, Vol. 14, Núm. 16, pp. 1451-1457

  2. Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study

    Atherosclerosis, Vol. 295, pp. 45-53

  3. Endothelial shear stress and vascular remodeling in bioresorbable scaffold and metallic stent

    Atherosclerosis, Vol. 312, pp. 79-89

2019

  1. Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease: Twoyear follow-up of the SYNTAX II study

    EuroIntervention, Vol. 15, Núm. 3, pp. E244-A252

  2. Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study

    American Heart Journal, Vol. 209, pp. 97-105

  3. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial

    The Lancet, Vol. 393, Núm. 10175, pp. 987-997

2018

  1. Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial

    PLoS ONE, Vol. 13, Núm. 8

  2. First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial

    EuroIntervention

  3. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial)

    EuroIntervention, Vol. 13, Núm. 13, pp. 1561-1564

  4. Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy

    EuroIntervention, Vol. 14, Núm. 5, pp. e570-e579

  5. Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)

    EuroIntervention, Vol. 14, Núm. 11, pp. E1224-E1226

  6. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

    The Lancet, Vol. 392, Núm. 10151, pp. 940-949

2017

  1. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study

    European Heart Journal, Vol. 38, Núm. 42, pp. 3124-3134

  2. Comparison of everolimus-eluting bioresorbable scaffolds with everolimuseluting metallic stents for treatment of coronary artery stenosis: Three-year follow-up of the ABSORB II randomized trial

    Bioresorbable Scaffolds: From Basic Concept to Clinical Applications (CRC Press), pp. 224-237

  3. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy

    JACC: Cardiovascular Interventions, Vol. 10, Núm. 18, pp. 1867-1877

2016

  1. Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: Rationale and design of the randomised TROFI II study

    EuroIntervention, Vol. 12, Núm. 4, pp. 482-489

  2. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial

    The Lancet, Vol. 387, Núm. 10016, pp. 357-366